Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

Exposure–response analyses of upadacitinib (UPA) key efficacy and safety end points (3,685 and 4,577 subjects for efficacy and safety, respectively) using data from phase II and phase III rheumatoid arthritis (RA) studies were conducted to support benefit–risk assessment. Percentage of subjects achi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Pharmacol Ther
Main Authors: Nader, Ahmed, Mohamed, Mohamed‐Eslam F., Winzenborg, Insa, Doelger, Eva, Noertersheuser, Peter, Pangan, Aileen L., Othman, Ahmed A.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2019
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7158206/
https://ncbi.nlm.nih.gov/pubmed/31610021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1671
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker